ABS Vaccines Blog
Candidate Vaccines for COVID-19
With over 3 million confirmed cases of COVID-19 worldwide, we all hold onto the hope of finding the drug that can help end the pandemic.
Since the world became aware of the new SARS-CoV-2 virus strain that causes COVID-19, a respiratory illness, scientists and researchers around the globe have been on a relentless hunt for drugs and vaccines to treat the disease.
Vaccination is one of the most effective ways of training our immune system to protect against diseases. This works by introducing a small number of antigens, (a weakened or inactive version of the disease-causing pathogen) so that the body can trigger an immune response to it, therefore, producing antibodies that will fight the virus or bacteria once it re-enters the body.
The development of new vaccines can take years. From initial studies to safety and effectiveness testing, approval to mass production - a vaccine for COVID-19 can take 12 to 18 months or longer to become available. On a positive note, researchers are using past research on SARS and MERS vaccines putting us a few steps ahead on the development of this new vaccine.
Here is where we stand according to the WHO draft landscape of COVID-19 vaccine candidates published on April 26th, 2020. There are 7 candidate vaccines in clinical evaluation:
Non-Replicating Viral Vector Adenovirus Type 5 Vector CanSino Biological Inc./ Beijing Institute of Biotechnology Phase 1 & Phase 2
Non-Replicating Viral Vector ChAdOx1 University of Oxford Phase 1/2
DNA DNA plasmid vaccine with electroporation Inovio Pharmaceuticals Phase 1
Inactivated Inactivated Beijing Institute of Biological Products/ Wuhan Institute of Biological Products Phase 1
Inactivated Inactivated + alum Sinovac Phase 1
RNA mRNA BioNTech/ Fosun Pharma/ Pfizer Phase 1/2
RNA LNP-encapsulated mRNA Moderna/NIAID Phase 1
There are 82 candidate vaccines in preclinical evaluation, you can access the landscape document here: https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines
ABS offers savings on GSK Vaccines
ABS Vaccines members find substantial savings on GSK Vaccines through the ABS Vaccines agreement.